News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
185 Results
Type
Article (15)
Press Release (170)
Section
Business (68)
Deals (12)
Drug Development (29)
FDA (7)
Job Trends (1)
News (109)
Policy (10)
Tag
Alliances (7)
Approvals (7)
Best Places to Work (1)
Clinical research (27)
Collaboration (1)
Data (2)
Earnings (44)
Events (40)
Executive appointments (1)
FDA (8)
GLP-1 (1)
Healthcare (2)
IPO (12)
Legal (1)
Medical device (3)
Medtech (3)
Mergers & acquisitions (1)
Multiple sclerosis (1)
Neuroscience (1)
NextGen Class of 2024 (2)
Pain (3)
People (19)
Phase I (2)
Phase II (7)
Phase III (22)
Pipeline (2)
Regulatory (9)
Startups (1)
United States (16)
Date
Today (1)
Last 7 days (3)
Last 30 days (6)
Last 365 days (37)
2024 (37)
2023 (27)
2022 (36)
2021 (30)
2020 (31)
2019 (8)
2018 (12)
2017 (2)
2016 (2)
Location
Asia (10)
Australia (1)
China (1)
Europe (2)
New York (16)
185 Results for "eyenovia".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Drug Development
Eyenovia Shares Plummet 70% After It Drops Lead Program
Eyenovia’s stock craters to its lowest point in its six-year lifespan as a public company following the biotech’s termination of its lead program in pediatric progressive myopia due to lack of efficacy.
November 15, 2024
·
2 min read
·
Heather McKenzie
Biotech Bay
NovaBay Pharmaceuticals and Eyenovia Commence Co-Promotion Activities
NovaBay® Pharmaceuticals, Inc. and Eyenovia, Inc. have commenced activities under a previously announced co-promotion agreement.
July 1, 2024
·
8 min read
Press Releases
Eyenovia Provides Update on Phase 3 CHAPERONE Study
November 15, 2024
·
5 min read
Pharm Country
Eyenovia Announces Pricing of $5M Registered Direct Offering
Eyenovia, Inc. providing for the purchase and sale of 7,575,757 shares of common stock, and warrants to purchase up to 7,575,757 shares of common stock.
June 28, 2024
·
5 min read
Press Releases
Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 13, 2024
·
11 min read
Press Releases
Eyenovia to Report Third Quarter 2024 Results on Tuesday, November 12th
November 8, 2024
·
2 min read
Press Releases
Eyenovia Announces Publication of Study Demonstrating Favorable Impact on the Ocular Surface of Medication Delivered with the Optejet®
October 24, 2024
·
6 min read
Press Releases
Eyenovia Announces Commencement of Manufacturing of its Advanced, Second Generation Optejet Device
October 1, 2024
·
4 min read
Pharm Country
Eyenovia Provides Clinical and Scientific Update on FDA-Approved Products Mydcombi™ and Clobetasol Propionate Ophthalmic Suspension
Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic company, today provided an update on its two FDA-approved products.
April 25, 2024
·
10 min read
Press Releases
Eyenovia Announces Presentation of Phase 3 Clobetasol Study Results at the American Academy of Ophthalmology (AAO) 2024 Expo
October 16, 2024
·
4 min read
1 of 19
Next
